Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments (Q37926944)

25 August 2017

1 reference

title

Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

25 August 2017

0 references

1 reference

non-alcoholic fatty liver

inferred from title

1 reference

1 reference

E Scorletti

1

1 reference

PubMed ID

21894514

25 August 2017

P C Calder

series ordinal

2

1 reference

PubMed ID

21894514

25 August 2017

C D Byrne

series ordinal

3

1 reference

25 August 2017

6 September 2011

1 reference

25 August 2017

1 reference

25 August 2017

40

1 reference

25 August 2017

3

1 reference

25 August 2017

332-343

1 reference

https://scigraph.springernature.com/pub.10.1007/s12020-011-9530-x

25 August 2017

0 references

cites work

Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Serum markers detect the presence of liver fibrosis: a cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Fatty liver: a novel component of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Formation of cholesteryl ester-rich particulate lipid during metabolism of chylomicrons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Metabolic disturbances in non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Effect of weight loss on VLDL-triglyceride and apoB-100 kinetics in women with abdominal obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Metabolic effects of fructose and the worldwide increase in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Dietary fructose and intestinal barrier: potential risk factor in the pathogenesis of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Sweetened beverage consumption and risk of coronary heart disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

The concept of allostasis in biology and biomedicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Are there persons who are obese, but metabolically healthy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome--an allostatic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Fatty liver: role of inflammation and fatty acid nutrition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Trans fatty acids and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Trans fatty acids and weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Repeatability and measurement error in the assessment of choline and betaine dietary intake: the Atherosclerosis Risk in Communities (ARIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Choline: an essential nutrient for public health

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Phosphatidylcholine and choline homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Biochemical and evolutionary significance of phospholipid methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Impaired de novo choline synthesis explains why phosphatidylethanolamine N-methyltransferase-deficient mice are protected from diet-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Plasma homocysteine is regulated by phospholipid methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Lack of phosphatidylethanolamine N-methyltransferase alters plasma VLDL phospholipids and attenuates atherosclerosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Decreased survival of subjects with elevated liver function tests during a 28-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Causes and metabolic consequences of Fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Therapeutic effects of restricted diet and exercise in obese patients with fatty liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Changes in emerging cardiac biomarkers after an intensive lifestyle intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

The associations of physical activity and adiposity with alanine aminotransferase and gamma-glutamyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Cardiovascular effects of marine omega-3 fatty acids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

The fatty acid composition of plasma cholesteryl esters and estimated desaturase activities in patients with nonalcoholic fatty liver disease and the effect of long-term ezetimibe therapy on these levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Thiazolidinediones and the liver in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9530-X

Serum alanine aminotransferase levels decrease further with carbohydrate than fat restriction in insulin-resistant adults

21 January 2018

1 reference

12 December 2020

Reversal of hepatic steatosis by omega-3 fatty acids measured non-invasively by (1) H-magnetic resonance spectroscopy in a rat model

1 reference

12 December 2020

Novel role of NPC1L1 in the regulation of hepatic metabolism: potential contribution of ezetimibe in NAFLD/NASH treatment

1 reference

12 December 2020

Impaired phosphatidylcholine biosynthesis reduces atherosclerosis and prevents lipotoxic cardiac dysfunction in ApoE-/- Mice

1 reference

12 December 2020

The epidemiologic transition. A theory of the Epidemiology of population change. 1971.

1 reference

12 December 2020

Origins and evolution of the Western diet: health implications for the 21st century

1 reference

12 December 2020

Role of human liver lipogenesis and reesterification in triglycerides secretion and in FFA reesterification

1 reference

12 December 2020

The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

1 reference

12 December 2020

Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction

1 reference

12 December 2020

Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis

1 reference

12 December 2020

Intermediary metabolism of fructose

1 reference

12 December 2020

Fructose impairs glucose-induced hepatic triglyceride synthesis

1 reference

12 December 2020

Human health in nature--towards a holistic philosophy of nutrition.

1 reference

12 December 2020

Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease

1 reference

12 December 2020

Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease

1 reference

12 December 2020

Mitochondrial dysfunction in the liver of type 2 diabetic Goto-Kakizaki rats: improvement by a combination of nutrients

1 reference

12 December 2020

Fifth phase of the epidemiologic transition: the age of obesity and inactivity

1 reference

12 December 2020

Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance

1 reference

12 December 2020

10.1007/S12020-011-9530-X

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

21894514